ArticleBioprocess and biosystems engineering2026
A three-step serum-free protocol for the robust generation of monocyte-derived dendritic cells from human hematopoietic stem/progenitor cells.
Article in Bioprocess and biosystems engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Dendritic cells (DCs) and their monocyte precursors are rare in peripheral blood, which limits their use in immunotherapy. Although hematopoietic stem/progenitor cells (HSPCs) provide an alternative source, they are even less abundant in vivo. To address this limitation and compensate for apoptosis during the generation of DCs from monocytes, we developed a three-step serum-free protocol (culture system) that combines HSPC expansion with sequential differentiation. The protocol comprises a 7-day HSPC expansion phase, a 14-day monocyte induction phase, and a 7-day DC generation phase-5 days of differentiation followed by 2 days of maturation with either tumor necrosis factor-α or lipopolysaccharide. Cell quantification revealed that the system generated approximately 5,000 monocytes and 50 DCs from a single HSPC. The generated DCs expressed the key surface markers CD40 and CD209 and exhibited antigen uptake capacity comparable to that of native CD14⁺ monocyte-derived DCs. Overall, this system provides a reproducible and scalable platform for studying DC biology and supports applications in preclinical and translational immunotherapy research.
Indexed as
Identifiers
42862295What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.